Sale!

Enorma Post Menopausal Bone & Joint Health

450.00

  • Helps to Prevent Bone Fracture, Increase the level of Calcium Formation in Bones and Maintain the Bone Mineral Density.

Also, Shop At –

Clear
SKU: N/A Category:

Description

Why Enorma Post-Menopausal Bone & Joint Health?
Our product contains, Guggul Extract, Ajuna (Terminalia arjuna) Extract, Ashwagandha Extract, Soy Isoflavone and Lycopene helps in Preventing Bone Fractures, Calcium Citrate Maleate helps to Maintain the level of Calcium formation in Bones and Phellodendron Extract, Magnesium, Vitamin D (Ergocalciferol), Vitamin K2 (as MK-7), Copper, Manganese and Zinc helps to Maintain Bone Mineral Density, leading Stronger Bone Formation.

Basis Esperer Nutrition proprietary research on DINI Axis (DIET-INFECTION- NUTRITION- IMMUNITY) outcome which addresses the association between diet and an infectious risk factor for lifestyle chronic disease. DINI confirms Therapeutic Nutritional Interventions through Immunomodulatory Pathways to improve patient’s quality of life. DINI Axis is carefully integrated into Esperer Nutrition portfolio which prevents and manages the disease better.

Nutritional Information

Rational

EON’s nutritional product enriched with major ingredients such as Guggul Extract, Arjuna (Terminalia arjuna) Extract, Cissus quadrangularis and Soya Isoflavone for treatment of Post-Menopausal Osteoporosis.

Introduction:

Osteoporosis is a disease that weakens bones, increasing the risk of sudden and unexpected fractures. Literally meaning “porous bone,” osteoporosis results in an increased loss of bone mass and strength. The disease often progresses without any symptoms or pain. There is a direct relationship between the lack of estrogen during perimenopause, menopause and post menopause and the development of osteoporosis. Early menopause (before age 45) and any prolonged periods in which hormone levels are low and menstrual periods are absent or infrequent can cause loss of bone mass.
During the menopausal transition period, the drop of estrogen leads to more bone resorption than formation, resulting in osteoporosis.

Problems associated with osteoporosis(post-menopausal): The symptoms which occurs due to osteoporosis(post-menopausal) are:

  • Fracture – Fracture is most common symptom since the strength of the bones reduces after menopause.
  • Low level of calcium formation – The strength of bones gets reduced since calcium deficiency is observed after menopause.
  • Reduction in bone mineral density – Bone mineral density is not maintained, leading to fractures.

To overcome the symptoms of osteoporosis(post-menopausal), Eon’s product contains major ingredients such as Guggul Extract, Arjuna (Terminalia arjuna) Extract, Cissus quadrangularis and Soya Isoflavone for treatment of osteoporosis(post-menopausal) and its associated symptoms.

  • Guggul Extract – Guggul extract, a resinous exudate of the plant Commiphora mukul Engl. (Burseraceae) helps in the treatment of bone fractures and it shows significant gain in bone strength and nearly complete restoration of bone microarchitecture along with lowered levels of tartrate-resistant acid phosphatase (TRAP) indicating the anti-bone resorptive potential of the extract. Constituents of guggul (guggulstrerone ) have shown to have immunomodulatory effect and it was discovered that the receptor activator of NF-kB ligand (RANKL) is a major intermediary in diseases associated with enhanced bone resorption. RANKL is a member of the tumour necrosis factor (TNF) superfamily. It is now known that guggulsterone antagonizes the farnesoid X receptors (FXR), inhibits the activation of NF-kB and thus suppresses bile-acid gene expression. Results showed that guggulsterone blocks RANKL signalling and osteoclastogenesis induced by RANKL by inhibiting the activity of IkBa kinase. Guggulsterone treatment also induces phosphorylation and further degradation of IkBa, which is an inhibitor of NF-kB. Dose-dependent and time-dependent treatment with guggulsterone suggested suppression of monocyte differentiation into osteoclasts.
  • Arjuna (Terminalia arjuna) Extract – Arjuna (Terminalia arjuna) Extract helps to increase the rate of ossification of bone which help to cure bone fracture, osteoporosis and calcium deficiency related problems. The haemagglutination titre test was performed to assess the effect of T.arjuna on humoral immune response. T.arjuna significantly increased the secondary immune response, as evidenced by an increase in the anti-SRBC antibody titre, but failed to modulate the primary immune response. Thus, T.arjuna bark powder can also be said to possess some immunomodulatory activity. Naloxone, an opioid receptor antagonist, increases IL-2 and interferon gamma levels but decreases the production of IL-4 in BALB/C mice. The effect of naloxone could be ascribed to the removal of regulatory effects of endogenous opioid peptides on cytokine production. There have been reports, indicating that an opioid receptor agonist, morphine, has downregulated the phagocytic cell function particularly human peripheral blood mononuclear cells (PBMCs) and neutrophils. Further, phagocytosis, chemotaxis, IL production, generation of active oxygen intermediates and arachidonic acid products have also been reduced by morphine. Mediratta et al also reported the role of endogenous opioids in modulation of humoral immune response and antigen-induced histamine release from mixed peritoneal cells of rats. Thus, it can be suggested that T.arjuna which probably has effect on opioidergic system, may have some role in inflammation and immunomodulation as well.
  • Cissus quadrangularis – Cissus quadrangularis (CQ) helps in the treatment of osteoporosis induced by ovariectomy. It is well known that estrogen deficiency is an important risk factor in the pathogenesis of osteoporosis. Estrogen influences bone loss either directly by binding to the receptor on the bone or indirectly by influencing calcium regulatory hormones (parathyroid hormone (PTH) and vitamin D) and cytokines interleukin (IL)-1 and Interleukin (IL)-6. Ethanolic extract of C. quadrangularis increased WBC counts and bone marrow cells that stimulate hemopoetic system resulting in the activation of immunomodulatory activity in delayed-type hypersensitivity (DTH) reaction. C. quadrangularis showed a significant increase in the serum immunoglobulin levels as evident by zinc sulphate turbidity test. This test provides a rough estimation of the amount of immunoglobulins present in the serum. Zinc sulphate causes precipitation of the immunoglobulins making the solution cloudy. The estimation of serum immunoglobulin levels is used to evaluate the increase in serum immunoglobulin production after the administration of the drugs. The ethanolic extract of C. quadrangularis enhances serum immunoglobulin level, WBC count, exerting beneficial effect on immune system. C. quadrangularis was found to have a significant immunostimulatory activity on both the specific and nonspecific immune mechanisms.
  • Soya Isoflavone – Soy isoflavones prevents postmenopausal osteoporosis and improve bone strength, thereby decreasing risk of fracture in menopausal women by increasing lumbar spine BMD and decreasing the bone resorption marker urine DPD.
    Constituents of soya isoflavones (genistein) have shown immunomodutory effect. Estrogen receptor dependent and independent mechanisms have been proposed for the immune modulating effect of genistein since genistein is structurally similar to estrogen. Indeed, expression of the estrogen receptor in thymocytes, lymphocytes and macrophages has been reported. It is possible that genistein has estrogen – like action and modulates immune function mediated by the estrogen receptor. However, several studies have shown that blockade of the estrogen receptor pathway partially abolishes the action of genistein. Genistein is known to be a broad- spectrum protein tyrosine kinase inhibitor and its activity may contribute to one of the estrogen receptor – independent mechanisms. In vitro experiments have shown that genistein at a dose of more than 10μM inhibits both tyrosine phosphorylation and binding of the nuclear factor to the specific promoter region, resulting in inhibition of proliferation response and cytokine production.

References:

    1. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20(6 Suppl. 28), S152–S157 (2002).
    2. Little CV, Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst. Rev. 1, CD002947 (2001).
    3. Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann. Intern. Med. 131(6),409–416 (1999).
    4. Meryl S L, Metabolic Bone Diseases: Text book of Rheumatology, 5th edn, WB Saunders Co., London, 1997,1563-72.

Clinical Trial ID

Description

  Duration

Indication

Sponsor/ Agency

NCT01463436 To study the effect of soy isoflavone supplementation on endothelial function. (Phase 3) 2010-2011 Osteoporosis Trisakti University
NCT00661856 To study the effect of soy isoflavones on bone mineral density and physical performance indices (SoyPTI). (Phase NA) 2001-2004 Osteoporosis Creighton University
NCT00244907 To study the effect of isoflavones for promoting calcium absorption and preventing bone loss in post-menopausal women. (Phase 1) 2006-2010 Osteoporosis Purdue University
NCT00668447 The purpose of this study is to test the effect of 1 year of added dietary soy protein and/or soy isoflavones on bone mineral density in late postmenopausal women. (Phase 4) 2001-2005 Osteoporosis United States Department of Agriculture (USDA)
    5. Gruber H E, Ivey J L, Baylink D J, Matthews M, Nelp W B, Sisom K and Chesnut C H 3rd, Long term calcitonin therapy in postmenopausal osteoporosis, Metabolism, 1984, 33, 295- 303.
    6. Turner R T, Riggs B L and Spielberg T C, Skeletal effects of estrogen, Endocr Rev, 1994, 15, 275-300.
    7. Bahram, H.A., Lee, A., Bruce, W.H., Daxa, A., Maria, S., Peilin, G., Subhas, C.K., 1996. Dietary soybean prevents bone loss in an ovariectomized rat model of osteoporosis. The Journal of Nutrition 126, 161–167.
    8. Bennet, A.E., Wahner, H.W., Riggs, B.L., 1984. Soya—a dietary source of the non-steroidal oestrogen equal in man and animals. Journal of Endocrinology 102, 49–56.
    9. Canalis, H., McCarthy, T., Centrella, M., 1998. Growth factors and the regulation on bone remodeling. Journal of Clinical Investigation 81, 277–281.

    10. Kumbhojkar, M.S., Kulkarni, D.K., Upadhye, A.S., 1991. Ethnobotany of Cissus quadrangularis L. from India. Ethnobotany 3, 21– 25.

Our approach Eon’s product contains major ingredients such as Guggul Extract, Arjuna (Terminalia arjuna) Extract, Cissus quadrangularis and Soya Isoflavone, along with other ingredients which helps to treat post-menopausal osteoporosis and its associated symptoms. Below we present the formula of the product.

Formula:

Serving Size: 1 Tablet UNIT   Specification
Energy Kcal TBD
Protein g TBD
Fat g TBD
Carbohydrate g TBD
Sugar (Sucrose) g TBD
Guggul Extract mg 65 5% Guggulsterone
Arjuna (Terminalia arjuna) Extract mg 45
Cissus quadrangularis mg 50 40% Ketosterone
Ashwagandha Extract mg 50 5% Withaniolide
Soya Isoflavone mg 40 40% Isoflavone
Phellodendron Extract mg 90 Berberine Hydrochloride 95%
Calcium citrate maleate mg 500 Calcium source
Magnesium mg 50 Magnesium Oxide
Vitamin D (Ergocalciferol) IU 200 Ergocalciferol
Vitamin K2 (as MK-7) mcg 25 MK-7
Copper mg 1.5 Available source
Manganese mg 2.5 Available Source
Zinc mg 9 Available Source
Lutein mcg 475 Available Source
Astaxanthin mcg 475 Available Source
Lycopene mcg 475 Available Source

FAQ

1. Does Enorma Post Menopausal Bone & Joint Health have any side effects?
Our products comprise the highest quality ingredients and are safe to consume when used as per the stated label. However, please consult a health practitioner if you have any prior medical conditions.

2. What is Post Menopausal Osteoporosis?
Osteoporosis is a disease that weakens bones, increasing the risk of sudden and unexpected fractures. Meaning “porous bone,” osteoporosis results in an increased loss of bone mass and strength. The disease often progresses without any symptoms or pain. There is a direct relationship between the lack of oestrogen during perimenopause, menopause and post menopause and the development of osteoporosis. Early menopause (before age 45) and any prolonged periods in which hormone levels are low and menstrual periods are absent or infrequent can cause loss of bone mass. Post menopausal osteoporosis is associated with symptoms such as fracture, low level of calcium formation in bone and reduction in bone mineral density.

3. What is the best time of the day to take a Post Menopausal Bone & Joint Health tablet?
Recommended Usage: “For Women” 1 Tablet once a day after a meal or as suggested by healthcare professionals

4. For how long do I need to use this product?
Use the product in continuation for at least 8 Weeks for effective results or as suggested by your Healthcare Professional.

5. What is the research on this product?
The product is developed by the research team who has profound experience in the world of nutrition. For more information, please visit the R&D innovation page on the website.

Reviews

There are no reviews yet.

Be the first to review “Enorma Post Menopausal Bone & Joint Health”

Your email address will not be published. Required fields are marked *